고용주 및 직장 약물 검사 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 방법별, 약물별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Employer And Workplace Drug Testing Market Summary

The global employer and workplace drug testing market size was estimated at USD 6.33 billion in 2025 and is projected to reach USD 9.09 billion by 2033, growing at a CAGR of 4.7% from 2026 to 2033. This market focuses on detecting the presence of illicit drugs and controlled substances in biological samples to support workplace safety, regulatory compliance, and productivity.

Testing methods such as urine, oral fluid, hair, and blood analysis are widely used across industries including transportation, manufacturing, construction, and energy to reduce workplace accidents and absenteeism. Employer and workplace drug testing plays a significant role in pre-employment screening, random testing, and post-incident investigations, helping organizations maintain a safe and compliant workforce. The demand is driven by stricter government regulations, corporate policies promoting drug-free environments, and the availability of advanced rapid testing kits and laboratory-based confirmation methods. Growing awareness of substance abuse impacts on workforce performance and safety is further encouraging adoption across both developed and emerging markets.

According to a national survey by American Addiction Centers, 15.3% of U.S. workers reported working under the influence of alcohol, while 2.9% admitted to being under the influence of illicit drugs in 2024. These figures underscore a significant challenge for U.S. employers, highlighting the need for strong workplace drug testing policies. Furthermore, there is a growing emphasis on workplace safety and productivity, prompting organizations to adopt measures that ensure a drug-free environment. Rising awareness of the adverse effects of substance misuse in the workplace, including reduced productivity, increased absenteeism, workplace accidents, and legal liabilities, further drives demand for drug testing services.

Moreover, advancements in drug testing technologies have made testing more accurate, efficient, and cost-effective, encouraging more employers to incorporate these solutions into their human resource practices. As organizations increasingly recognize the value of maintaining a safe and productive work environment, the market for workplace drug testing continues to expand.

Overall, innovation in the employer and workplace drug testing market is transforming the efficiency, accuracy, and scope of screening programs. Advances in portable devices and non-invasive sampling are making testing more convenient and less disruptive for both employers and employees, while sophisticated laboratory techniques are enhancing the ability to identify a broader range of substances with high precision. The integration of AI-driven data management and multi-panel rapid testing is streamlining operations, reducing costs, and supporting compliance with stringent regulatory requirements. These developments are enabling organizations to implement more proactive and reliable workplace drug testing strategies, strengthening safety and productivity across diverse industry sectors.

Global Employer And Workplace Drug Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the employer and workplace drug testing market based on type, product, mode, drug, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-employment drug screens
• Post-employment
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
• Instruments
• Rapid Testing Devices
• Services
• Mode Outlook (Revenue, USD Million, 2021 - 2033)
• Urine
• Hair
• Oral Fluid
• Instant testing
• Drug Outlook (Revenue, USD Million, 2021 - 2033)
• Alcohol
• Cannabis/Marijuana
• Cocaine
• Opioids
• Amphetamine & Methamphetamine
• LSD
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• IT/Finance
• Manufacturing
• Transportation
• Construction
• Retail and Hospitality
• Healthcare
• Education
• Other Professional Services
• Regional Outlook (Revenue, USD Million, 2021- 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Product Segment
  • 1.2.3. Mode Segment
  • 1.2.4. Drug Segment
  • 1.2.5. End-use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Employer and Workplace Drug Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for pre-employment testing
    • 3.2.1.2. Stringent laws mandating alcohol and drug testing in the workplace
    • 3.2.1.3. Rising prevalence of substance use in the workplace
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Changing legal environment and changing societal norms
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Technological advancement in drug testing for workplace
• 3.3. Global Employer and Workplace Drug Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Employer and Workplace Drug Testing Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Employer and Workplace Drug Testing Market Type Movement Analysis
• 4.3. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
• 4.4. Pre-employment Drug Screens
  • 4.4.1. Pre-employment drug screens market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Post-employment
  • 4.5.1. Post-employment market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Employer and Workplace Drug Testing Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Employer and Workplace Drug Testing Market Product Movement Analysis
• 5.3. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
• 5.4. Consumables
  • 5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Instruments
  • 5.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Rapid Testing Devices
  • 5.6.1. Rapid testing devices market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Services
  • 5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Employer and Workplace Drug Testing Market: Mode Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Employer and Workplace Drug Testing Market Mode Movement Analysis
• 6.3. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by mode, 2021 to 2033 (USD Million)
• 6.4. Urine
  • 6.4.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Hair
  • 6.5.1. Hair market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Oral Fluid
  • 6.6.1. Oral fluid market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Instant testing
  • 6.7.1. Instant testing market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Employer and Workplace Drug Testing Market: Drug Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Employer and Workplace Drug Testing Market Drug Movement Analysis
  • 7.2.1. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by drug, 2021 to 2033 (USD Million)
• 7.3. Alcohol
  • 7.3.1. Alcohol market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Cannabis/Marijuana
  • 7.4.1. Cannabis/marijuana market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Cocaine
  • 7.5.1. Cocaine market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Opioids
  • 7.6.1. Opioids testing market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Amphetamine & Methamphetamine
  • 7.7.1. Amphetamine & methamphetamine market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. LSD
  • 7.8.1. LSD market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. Others
  • 7.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Global Employer and Workplace Drug Testing Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Employer and Workplace Drug Testing Market End Use Movement Analysis
  • 8.2.1. Global Employer and Workplace Drug Testing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.3. IT/Finance
  • 8.3.1. IT/finance market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Manufacturing
  • 8.4.1. Manufacturing market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Transportation
  • 8.5.1. Transportation market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Construction
  • 8.6.1. Construction market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Retail and Hospitality
  • 8.7.1. Retail and hospitality market estimates and forecasts 2021 to 2033 (USD Million)
• 8.8. Healthcare
  • 8.8.1. Healthcare market estimates and forecasts 2021 to 2033 (USD Million)
• 8.9. Education
  • 8.9.1. Education surgical centers market estimates and forecasts 2021 to 2033 (USD Million)
• 8.10. Other Professional Services
  • 8.10.1. Other Professional Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Employer and Workplace Drug Testing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Share Analysis, 2025
• 10.4. List of Key Certification Providers/Scheme Owners
• 10.5. Company Profiles/Listing
  • 10.5.1. First Advantage
    • 10.5.1.1. Company overview
    • 10.5.1.2. Financial performance
    • 10.5.1.3. Product benchmarking
    • 10.5.1.4. Strategic initiatives
  • 10.5.2. Laboratory Corporation of America Holdings (Labcorp)
    • 10.5.2.1. Company overview
    • 10.5.2.2. Financial performance
    • 10.5.2.3. Product benchmarking
    • 10.5.2.4. Strategic initiatives
  • 10.5.3. Dragerwerk AG & Co. KGaA
    • 10.5.3.1. Company overview
    • 10.5.3.2. Financial performance
    • 10.5.3.3. Product benchmarking
    • 10.5.3.4. Strategic initiatives
  • 10.5.4. Bio-Rad Laboratories, Inc.
    • 10.5.4.1. Company overview
    • 10.5.4.2. Financial performance
    • 10.5.4.3. Product benchmarking
    • 10.5.4.4. Strategic initiatives
  • 10.5.5. Abbott
    • 10.5.5.1. Company overview
    • 10.5.5.2. Financial performance
    • 10.5.5.3. Product benchmarking
    • 10.5.5.4. Strategic initiatives
  • 10.5.6. Clinical Reference Laboratory Inc.
    • 10.5.6.1. Company overview
    • 10.5.6.2. Financial performance
    • 10.5.6.3. Product benchmarking
    • 10.5.6.4. Strategic initiatives
  • 10.5.7. Quest Diagnostics
    • 10.5.7.1. Company overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Product benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. Cordant Health Solutions
    • 10.5.8.1. Company overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Product benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. DISA Global Solutions
    • 10.5.9.1. Company overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Product benchmarking
    • 10.5.9.4. Strategic initiatives
  • 10.5.10. HireRight, LLC
    • 10.5.10.1. Company overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Product benchmarking
    • 10.5.10.4. Strategic initiatives
  • 10.5.11. OraSure Technologies, Inc.
    • 10.5.11.1. Company overview
    • 10.5.11.2. Financial performance
    • 10.5.11.3. Product benchmarking
    • 10.5.11.4. Strategic initiatives
  • 10.5.12. Psychemedics Corporation
    • 10.5.12.1. Company overview
    • 10.5.12.2. Financial performance
    • 10.5.12.3. Product benchmarking
    • 10.5.12.4. Strategic initiatives
  • 10.5.13. Omega Laboratories
    • 10.5.13.1. Company overview
    • 10.5.13.2. Financial performance
    • 10.5.13.3. Product benchmarking
    • 10.5.13.4. Strategic initiatives